SABRE CORP (SABR)

US78573M1045 - Common Stock

3.55  0 (0%)

After market: 3.55 0 (0%)

Fundamental Rating

2

Taking everything into account, SABR scores 2 out of 10 in our fundamental rating. SABR was compared to 133 industry peers in the Hotels, Restaurants & Leisure industry. Both the profitability and financial health of SABR have multiple concerns. SABR is valued expensive and it does not seem to be growing.



2

1. Profitability

1.1 Basic Checks

SABR had negative earnings in the past year.
In the past year SABR had a positive cash flow from operations.
In the past 5 years SABR reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: SABR reported negative operating cash flow in multiple years.

1.2 Ratios

SABR has a worse Return On Assets (-6.40%) than 83.08% of its industry peers.
SABR has a Return On Invested Capital (6.30%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -6.4%
ROE N/A
ROIC 6.3%
ROA(3y)-12.92%
ROA(5y)-11.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Operating Margin of SABR (9.35%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of SABR has declined.
SABR's Gross Margin of 58.80% is fine compared to the rest of the industry. SABR outperforms 70.77% of its industry peers.
SABR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 9.35%
PM (TTM) N/A
GM 58.8%
OM growth 3YN/A
OM growth 5Y-31.8%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.61%
GM growth 5Y14.66%

2

2. Health

2.1 Basic Checks

SABR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
SABR has more shares outstanding than it did 1 year ago.
SABR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SABR is higher compared to a year ago.

2.2 Solvency

SABR has an Altman-Z score of -0.29. This is a bad value and indicates that SABR is not financially healthy and even has some risk of bankruptcy.
SABR's Altman-Z score of -0.29 is on the low side compared to the rest of the industry. SABR is outperformed by 88.46% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.29
ROIC/WACC0.73
WACC8.67%

2.3 Liquidity

SABR has a Current Ratio of 1.02. This is a normal value and indicates that SABR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.02, SABR is in line with its industry, outperforming 57.69% of the companies in the same industry.
SABR has a Quick Ratio of 1.02. This is a normal value and indicates that SABR is financially healthy and should not expect problems in meeting its short term obligations.
SABR's Quick ratio of 1.02 is fine compared to the rest of the industry. SABR outperforms 61.54% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02

3

3. Growth

3.1 Past

SABR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.89%, which is quite impressive.
The Revenue has been growing slightly by 5.26% in the past year.
Measured over the past years, SABR shows a decrease in Revenue. The Revenue has been decreasing by -5.54% on average per year.
EPS 1Y (TTM)70.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)5.26%
Revenue growth 3Y29.65%
Revenue growth 5Y-5.54%
Sales Q2Q%3.28%

3.2 Future

The Earnings Per Share is expected to grow by 21.47% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 3.60% on average over the next years.
EPS Next Y65.55%
EPS Next 2Y54.27%
EPS Next 3Y36.61%
EPS Next 5Y21.47%
Revenue Next Year3.79%
Revenue Next 2Y4.4%
Revenue Next 3Y4.18%
Revenue Next 5Y3.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

3

4. Valuation

4.1 Price/Earnings Ratio

SABR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 17.63 indicates a rather expensive valuation of SABR.
69.23% of the companies in the same industry are more expensive than SABR, based on the Price/Forward Earnings ratio.
SABR's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.73.
Industry RankSector Rank
PE N/A
Fwd PE 17.63

4.2 Price Multiples

SABR's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.86

4.3 Compensation for Growth

SABR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SABR's earnings are expected to grow with 36.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y54.27%
EPS Next 3Y36.61%

0

5. Dividend

5.1 Amount

SABR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SABRE CORP

NASDAQ:SABR (1/6/2025, 4:50:53 PM)

After market: 3.55 0 (0%)

3.55

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-13 2025-02-13/amc
Inst Owners91.43%
Inst Owner Change0%
Ins Owners2.01%
Ins Owner Change3.07%
Market Cap1.37B
Analysts70
Price Target4.57 (28.73%)
Short Float %6.42%
Short Ratio5.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)-39.54%
DP-0.01%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.34%
Min EPS beat(2)-12.04%
Max EPS beat(2)38.73%
EPS beat(4)3
Avg EPS beat(4)31%
Min EPS beat(4)-12.04%
Max EPS beat(4)79.89%
EPS beat(8)5
Avg EPS beat(8)18.72%
EPS beat(12)7
Avg EPS beat(12)15%
EPS beat(16)9
Avg EPS beat(16)9.91%
Revenue beat(2)0
Avg Revenue beat(2)-1.9%
Min Revenue beat(2)-3.32%
Max Revenue beat(2)-0.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.07%
Min Revenue beat(4)-3.32%
Max Revenue beat(4)2.15%
Revenue beat(8)2
Avg Revenue beat(8)-1.57%
Revenue beat(12)3
Avg Revenue beat(12)-1.26%
Revenue beat(16)4
Avg Revenue beat(16)-2.66%
PT rev (1m)3.86%
PT rev (3m)3.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.63
P/S 0.46
P/FCF N/A
P/OCF 16.39
P/B N/A
P/tB N/A
EV/EBITDA 13.86
EPS(TTM)-0.23
EYN/A
EPS(NY)0.2
Fwd EY5.67%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.22
OCFY6.1%
SpS7.78
BVpS-4.04
TBVpS-11.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.4%
ROE N/A
ROCE 7.98%
ROIC 6.3%
ROICexc 7.78%
ROICexgc N/A
OM 9.35%
PM (TTM) N/A
GM 58.8%
FCFM N/A
ROA(3y)-12.92%
ROA(5y)-11.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-7.17%
ROICexc growth 3YN/A
ROICexc growth 5Y-31.33%
OM growth 3YN/A
OM growth 5Y-31.8%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.61%
GM growth 5Y14.66%
F-Score5
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 11.58
Cap/Depr 65.32%
Cap/Sales 2.89%
Interest Coverage 250
Cash Conversion 20.19%
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z -0.29
F-Score5
WACC8.67%
ROIC/WACC0.73
Cap/Depr(3y)39.05%
Cap/Depr(5y)32.59%
Cap/Sales(3y)2.99%
Cap/Sales(5y)3.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y65.55%
EPS Next 2Y54.27%
EPS Next 3Y36.61%
EPS Next 5Y21.47%
Revenue 1Y (TTM)5.26%
Revenue growth 3Y29.65%
Revenue growth 5Y-5.54%
Sales Q2Q%3.28%
Revenue Next Year3.79%
Revenue Next 2Y4.4%
Revenue Next 3Y4.18%
Revenue Next 5Y3.6%
EBIT growth 1Y1045.52%
EBIT growth 3YN/A
EBIT growth 5Y-35.58%
EBIT Next Year129.99%
EBIT Next 3Y45.79%
EBIT Next 5Y26.3%
FCF growth 1Y99.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.66%
OCF growth 3YN/A
OCF growth 5Y-40.09%